CNS Drugs

, Volume 23, Issue 4, pp 293–307

Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer’s Disease

Review Article

Abstract

The mainstay of current management of patients with Alzheimer’s disease involves drugs that provide symptomatic therapy. Research approaches for future therapy of Alzheimer’s disease are focusing on disease modifying and/or preventive approaches. Two classes of medications have been approved by the US FDA for the treatment of Alzheimer’s disease: the cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine), mostly for mild to moderate Alzheimer’s disease, and the noncompetitive NMDA receptor antagonist memantine for the moderate to severe stages of Alzheimer’s disease.

Management of comorbid medical problems can be more complex in patients with dementia than in those without dementia. Unfortunately, medication adherence in Alzheimer’s disease is low and good adherence is essential for attempting to slow disease progression and improve or stabilize quality of life. Simplifying treatment regimens and providing more caregiver- and patient-friendly modes of administration that fit in better with daily routines can ease caregiver stress which, in turn, may have a favourable impact on the patient’s condition. To overcome problems of medication adherence in the elderly, simple, user-friendly dosage regimens should be prescribed for all medications; thus the need for novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease, such as once-daily done-pezil, memantine and galantamine, and transdermal rivastigmine

References

  1. 1.
    Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003 Mar 4; 138(5): 400–10PubMedGoogle Scholar
  2. 2.
    Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003 Apr 3; 348(14): 1356–64PubMedCrossRefGoogle Scholar
  3. 3.
    Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000 Jul 25; 55(2): 198–204PubMedCrossRefGoogle Scholar
  4. 4.
    Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17; 366(9503): 2112–7PubMedCrossRefGoogle Scholar
  5. 5.
    Kosasa T, Kuriya Y, Matsui K, et al. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer’s disease, on cholinesterase activity in rats. Eur J Pharmacol 2000; 389: 173–9PubMedCrossRefGoogle Scholar
  6. 6.
    Yamada K, Takayanagi M, Kamei H, et al. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005; 162: 191–9PubMedCrossRefGoogle Scholar
  7. 7.
    Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457–9PubMedCrossRefGoogle Scholar
  8. 8.
    Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs 2000 Nov; 60(5): 1095–122PubMedCrossRefGoogle Scholar
  9. 9.
    Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr Drug Metab 2008 May; 9(4): 332–5PubMedCrossRefGoogle Scholar
  10. 10.
    Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003 Jan 8; 289(2): 210–6PubMedCrossRefGoogle Scholar
  11. 11.
    Bleich S, Romer K, Wiltfang J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003; 18: S33–40PubMedCrossRefGoogle Scholar
  12. 12.
    Danysz W, Parsons CG, Bresink I, et al. Glutamate in CNS disorders. Drug News Perspect 1995; 8: 261–77Google Scholar
  13. 13.
    Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18: S23–32PubMedCrossRefGoogle Scholar
  14. 14.
    Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 38: 735–67PubMedCrossRefGoogle Scholar
  15. 15.
    Brauner DJ, Muir JC, Sachs GA. Treating non dementia illnesses in patients with dementia. JAMA 2000 Jun 28; 283(24): 3230–5PubMedCrossRefGoogle Scholar
  16. 16.
    Karlawish JH, Casarett DJ, James BD, et al. The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology 2005 May 10; 64(9): 1514–9PubMedCrossRefGoogle Scholar
  17. 17.
    Pruchno RA, Smyer MA, Rose MS, et al. Competence of long-term care residents to participate in decisions about their medical care: a brief, objective assessment. Gerontologist 1995 Oct; 35(5): 622–9PubMedCrossRefGoogle Scholar
  18. 18.
    Morrison RS, Siu AL. Survival in end-stage dementia following acute illness. JAMA 2000 Jul 5; 284(1): 47–52PubMedCrossRefGoogle Scholar
  19. 19.
    Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicare program. J Am Geriatr Soc 2005; 53: 1269–70PubMedCrossRefGoogle Scholar
  20. 20.
    Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007 Nov; 23(11): 2705–13PubMedCrossRefGoogle Scholar
  21. 21.
    Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56Suppl. 1: 18–23PubMedGoogle Scholar
  22. 22.
    Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841–5PubMedCrossRefGoogle Scholar
  23. 23.
    Alzheimer’s Association. Statistics about Alzheimer’s disease [online]. Available from URL: http://www.alz.org/AboutAD/statistics.asp [Accessed 2006 Sep 18]
  24. 24.
    Connell CM, Janevic MR, Gallant MP. The costs of caring: the impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001; 14: 179–87PubMedCrossRefGoogle Scholar
  25. 25.
    Delagarza VW. Pharmacologic treatment of Alzheimer’s disease: an update. Am Fam Physician 2003; 68: 1365–72PubMedGoogle Scholar
  26. 26.
    Alzheimer’s Association and National Alliance for Caregiving. Families care: Alzheimer’s caregiving in the United States 2004 [online]. Available from URL: http://www.alz.org/national/documents/report_familiescare.pdf [Accessed 2009 Feb 2]
  27. 27.
    Slattum PW, Johnson MA. Caregiver burden in Alzheimer’s disease. Consult Pharm 2004; 19: 352–62PubMedCrossRefGoogle Scholar
  28. 28.
    Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000; 56: 501–9PubMedCrossRefGoogle Scholar
  29. 29.
    Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007; 69Suppl. 1: S4–9PubMedCrossRefGoogle Scholar
  30. 30.
    Sugimoto H, Iimura Y, Yamanishi Y, et al. Syntheses and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl] piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821–9PubMedCrossRefGoogle Scholar
  31. 31.
    Rogers SL, Yamanishi Y, Yamatsu K. E2020: thepharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston (MA): Birkhauser, 1991: 314–20Google Scholar
  32. 32.
    Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 Jul 31; 69(5): 459–69PubMedCrossRefGoogle Scholar
  33. 33.
    Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 2004; 486: 9–17PubMedCrossRefGoogle Scholar
  34. 34.
    Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol 2004 Nov; 58 Suppl. 1: 1–8CrossRefGoogle Scholar
  35. 35.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45Google Scholar
  36. 36.
    Weyer G, Erzigkeit H, Kanowski S, et al. Alzheimer’s disease assessment scale: reliability and validity in a multi-center clinical trial. Int Psychogeriatr 1997 Jun 2; 9(2): 123–38PubMedCrossRefGoogle Scholar
  37. 37.
    Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004 Jun 26; 363(9427): 2105–15PubMedCrossRefGoogle Scholar
  38. 38.
    Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003; (3): CD001190PubMedGoogle Scholar
  39. 39.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20PubMedCrossRefGoogle Scholar
  40. 40.
    Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20: 559–69PubMedCrossRefGoogle Scholar
  41. 41.
    Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624–33PubMedCrossRefGoogle Scholar
  42. 42.
    Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003 Jun; 51(6): 737–44PubMedCrossRefGoogle Scholar
  43. 43.
    Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007 May; 8(7): 1011–23PubMedCrossRefGoogle Scholar
  44. 44.
    Gander B, Meinel M, Walter E, et al. Polymers as a platform of drug delivery: reviewing our current portfolio on poly (lactide-coglycolide)(PLGA) microspheres. Chimia 2001; 55: 212–7Google Scholar
  45. 45.
    Pengcheng Z, Lingli C, Wangwen G, et al. In vitro and in vivo evaluation of donepezil-sustained release micro-particles for the treatment of Alzheimer’s disease. Biomaterials 2007 Apr; 28(10): 1882–8CrossRefGoogle Scholar
  46. 46.
    ClinicalTrials.gov. Comparison of 23 mg donepezil sustained release (SR) to 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer’s disease [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00478205 [Accessed 2009 Feb 2]
  47. 47.
    Harada CN, Shega JW, Sachs GA. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004 Dec 9; 351(24): 2509–18CrossRefGoogle Scholar
  48. 48.
    Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: relationship with age, sex and education. Neurology 1991; 41: 1886–92PubMedCrossRefGoogle Scholar
  49. 49.
    Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473–7PubMedCrossRefGoogle Scholar
  50. 50.
    Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer’s disease: epidemiology and management. Drugs Aging 2001; 18(11): 853–62PubMedCrossRefGoogle Scholar
  51. 51.
    Cummings J, Lefèvre G, Appel-Dingemanse S, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69(4 Suppl.): S10–3PubMedCrossRefGoogle Scholar
  52. 52.
    Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39PubMedCrossRefGoogle Scholar
  53. 53.
    Spencer CM, Noble S. Rivastigmine: a review on its use in Alzheimer’s disease. Drugs Aging 1998; 13: 391–411PubMedCrossRefGoogle Scholar
  54. 54.
    Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 1998; 20: 634–47PubMedCrossRefGoogle Scholar
  55. 55.
    Feldman H, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007 Oct; 78(10): 1056–63PubMedCrossRefGoogle Scholar
  56. 56.
    Exelon® patch: US prescribing information. East Hanover (NJ): Novartis, 2007 [online]. Available from URL: http://www.pharma.us.novartis.com/newsroom/press-release.jsp?PRID=2026 [Accessed 2009 Feb 2]
  57. 57.
    Lefèvre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008 Feb; 48(2): 246–52PubMedCrossRefGoogle Scholar
  58. 58.
    Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69(4 Suppl. 1): S14–22PubMedCrossRefGoogle Scholar
  59. 59.
    Cummings J, Lefèvre G, Small G, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: S10–3PubMedCrossRefGoogle Scholar
  60. 60.
    Winblad B, Fillit H, for the IDEAL study investigators. AD caregivers prefer patches to pills [platform presentation]. Festival of International Conferences on Caregiving, Disability, Aging and Technology; 2007 Jun 16–19; Toronto (ON)Google Scholar
  61. 61.
    Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69(4 Suppl. 1): S23–8PubMedCrossRefGoogle Scholar
  62. 62.
    Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22(5): 456–67PubMedCrossRefGoogle Scholar
  63. 63.
    Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2001; (1): CD001747PubMedGoogle Scholar
  64. 64.
    Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000 Dec 9; 321(7274): 1445–9PubMedCrossRefGoogle Scholar
  65. 65.
    Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174(8): 1099–105PubMedCrossRefGoogle Scholar
  66. 66.
    Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004 Feb; 61(2): 252–6PubMedCrossRefGoogle Scholar
  67. 67.
    Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004 Jul; 52(7): 1070–6PubMedCrossRefGoogle Scholar
  68. 68.
    Morris JC, Farlow MR, Ferris SH, et al. Therapeutic continuity in Alzheimer’s disease: switching patients to galantamine [panel discussion]: recommendations for prescribers. Clin Ther 2001; 23Suppl. A: 31CrossRefGoogle Scholar
  69. 69.
    Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment [letter]. BMJ 2005 Feb 5; 330(7486): 276PubMedCrossRefGoogle Scholar
  70. 70.
    Ortho-McNeil Neurologics Inc. Reminyl (galantamine hydrobromide) renamed Razadyne (galantamine hydrobromide) in U.S. to support patient safety [online]. Available from URL: http://www.jnj.com [Accessed 2006 Mar 15]
  71. 71.
    Zhao Q, Janssens L, Verhaeghe T, et al. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005 Oct; 21(10): 1547–54PubMedCrossRefGoogle Scholar
  72. 72.
    Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005 Apr; 21(4): 483–7PubMedCrossRefGoogle Scholar
  73. 73.
    Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20(2-3): 120–32PubMedCrossRefGoogle Scholar
  74. 74.
    Suh GH, Yeon Jung H, Uk Lee C, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. Korean Galantamine Study Group. Clin Ther 2004 Oct; 26(10): 1608–18PubMedCrossRefGoogle Scholar
  75. 75.
    Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006; 20(8): 673–81PubMedCrossRefGoogle Scholar
  76. 76.
    Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel group, 6-month study. Clin Ther 2006 Mar; 28(3): 365–72PubMedCrossRefGoogle Scholar
  77. 77.
    Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116: 331–47PubMedCrossRefGoogle Scholar
  78. 78.
    Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91–104Google Scholar
  79. 79.
    Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–24PubMedCrossRefGoogle Scholar
  80. 80.
    Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41PubMedCrossRefGoogle Scholar
  81. 81.
    Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46PubMedCrossRefGoogle Scholar
  82. 82.
    Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 49–54PubMedCrossRefGoogle Scholar
  83. 83.
    McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154PubMedGoogle Scholar
  84. 84.
    Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24 week randomized, controlled trial. Memantine MEM-MD-10 Study Group. Am J Geriatr Pyschiatry 2004; 14: 704–15CrossRefGoogle Scholar
  85. 85.
    Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004 Dec; 2(4): 303–12PubMedCrossRefGoogle Scholar
  86. 86.
    Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005 Aug 9; 65(3): 481–2PubMedCrossRefGoogle Scholar
  87. 87.
    Ott BR, Blake LM, Kagan E, et al. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol 2007 Mar; 254(3): 351–8PubMedCrossRefGoogle Scholar
  88. 88.
    Doody RS, Geldmacher DS, Gordon B, et al. Open label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427–33PubMedCrossRefGoogle Scholar
  89. 89.
    Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8Google Scholar
  90. 90.
    Jones R, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22: 258–62PubMedCrossRefGoogle Scholar
  91. 91.
    Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007; 46: 599–612PubMedCrossRefGoogle Scholar
  92. 92.
    Van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Memantine MEM-MD-01 Study Group. Alzheimer Dis Assoc Disord 2007 Apr–Jun; 21(2): 136–43CrossRefGoogle Scholar
  93. 93.
    Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRefGoogle Scholar
  94. 94.
    Jones R, Bayer A, Inglis F, et al. Once-daily dosing of memantine found to be as safe and tolerable as twice-daily dosing in a 12-week, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatr 2007; 22: 258-62CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Division of Geriatric MedicineSt Louis University Health Sciences Center, St LouisMissouriUSA
  2. 2.Department of Neurology and PsychiatrySt Louis University Health Sciences CenterSt LouisUSA

Personalised recommendations